Tonix Pharmaceuticals Holding Corp. Publishes Investor Presentation on TONMYA Fibromyalgia Launch and USD 208 million Cash Balance

Reuters

03/10

Tonix Pharmaceuticals Holding Corp. Publishes Investor Presentation on TONMYA Fibromyalgia Launch and USD 208 million Cash Balance

Tonix said it had about USD 208 million in cash as of Dec. 31, 2025, and reported no debt. The company said it expects its cash runway to extend into Q1 2027. Tonix reported USD 1.4 million in net sales for TONMYA over the period from Nov. 17 to Dec. 31, 2025. Tonix said TONMYA wholesale acquisition cost prices are USD 1,860 for a 60-count prescription and USD 930 for a 30-count prescription. The presentation also references Tonix’s marketed migraine products TOSYMRA and ZEMBRACE SymTouch, and includes links to their prescribing information: Patient Information and Patient Information.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on March 09, 2026, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2618673459"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618673459\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618673459?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 01:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618673459","market":"fut","top_or_hot":-1,"title":"Tonix Pharmaceuticals Holding Corp. Publishes Investor Presentation on TONMYA Fibromyalgia Launch and USD 208 million Cash Balance","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Tonix Pharmaceuticals Holding Corp. Publishes Investor Presentation on TONMYA Fibromyalgia Launch and USD 208 million Cash Balance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tonix said it had about USD 208 million in cash as of Dec. 31, 2025, and reported no debt. The company said it expects its cash runway to extend into Q1 2027. Tonix reported USD 1.4 million in net sales for TONMYA over the period from Nov. 17 to Dec. 31, 2025. Tonix said TONMYA wholesale acquisition cost prices are USD 1,860 for a 60-count prescription and USD 930 for a 30-count prescription. The presentation also references Tonix’s marketed migraine products TOSYMRA and ZEMBRACE SymTouch, and includes links to their prescribing information: Patient Information and Patient Information.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on March 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tonix Pharmaceuticals Holding Corp. Publishes Investor Presentation on TONMYA Fibromyalgia Launch and USD 208 million Cash Balance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTonix Pharmaceuticals Holding Corp. Publishes Investor Presentation on TONMYA Fibromyalgia Launch and USD 208 million Cash Balance\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2026-03-10 01:04</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Tonix Pharmaceuticals Holding Corp. Publishes Investor Presentation on TONMYA Fibromyalgia Launch and USD 208 million Cash Balance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tonix said it had about USD 208 million in cash as of Dec. 31, 2025, and reported no debt. The company said it expects its cash runway to extend into Q1 2027. Tonix reported USD 1.4 million in net sales for TONMYA over the period from Nov. 17 to Dec. 31, 2025. Tonix said TONMYA wholesale acquisition cost prices are USD 1,860 for a 60-count prescription and USD 930 for a 30-count prescription. The presentation also references Tonix’s marketed migraine products TOSYMRA and ZEMBRACE SymTouch, and includes links to their prescribing information: Patient Information and Patient Information.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on March 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TNXP","symbol_name":"Tonix Pharmaceuticals Holding Co","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDLShJ5X:1","article_id":"2618673459","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618673459","pubTimestamp":1773075843,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Tonix Pharmaceuticals Holding Corp. Publishes Investor Presentation on TONMYA Fibromyalgia Launch and USD 208 million Cash Balance. Tonix said it had about USD 208 million in cash as of Dec. 31, 2025, and reported no debt. The company said it expects its cash runway to extend into Q1 2027. Tonix reported USD 1.4 million in net sales for TONMYA over the period from Nov. 17 to Dec. 31, 2025. Tonix said TONMYA wholesale acquisition cost prices are USD 1,860 for a 60-count prescription and USD 930 for a 30-count prescription. The presentation also references Tonix’s marketed migraine products TOSYMRA and ZEMBRACE SymTouch, and includes links to their prescribing information: Patient Information and Patient Information.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TNXP":"Tonix Pharmaceuticals Holding Co","BK4583":"猴痘概念","BK4139":"生物科技"},"translate_title":"Tonix Pharmaceuticals Holding Corp.发布有关TONMYA纤维肌痛上市和2.08亿美元现金余额的投资者介绍","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TNXP":0.9},"content_text":"Tonix Pharmaceuticals Holding Corp. Publishes Investor Presentation on TONMYA Fibromyalgia Launch and USD 208 million Cash Balance\n    \n\n        Tonix said it had about USD 208 million in cash as of Dec. 31, 2025, and reported no debt. The company said it expects its cash runway to extend into Q1 2027. Tonix reported USD 1.4 million in net sales for TONMYA over the period from Nov. 17 to Dec. 31, 2025. Tonix said TONMYA wholesale acquisition cost prices are USD 1,860 for a 60-count prescription and USD 930 for a 30-count prescription. The presentation also references Tonix’s marketed migraine products TOSYMRA and ZEMBRACE SymTouch, and includes links to their prescribing information: Patient Information and Patient Information.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on March 09, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}